Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.

Jean Paul Salmon, Martin Smakal,Charisios Karanikiotis,Marek Z Wojtukiewicz, Yohann Omnes,Lucy DeCosta,Sally Wetten,James O'Kelly

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer（2019）

引用 7|浏览5

暂无评分

摘要

FN rates were consistent with previous reports with pegfilgrastim in clinical practice. No new ADRs were observed. G-CSF discontinuation was uncommon but appeared to increase the likelihood of neutropenic complications.

查看译文

关键词

Pegfilgrastim,Granulocyte-colony-stimulating factor,Prophylaxis,Discontinuation,Febrile neutropenia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要